This seminar will explore the key considerations around biotech valuations when preparing for out-licencing deals for specific assets, considering a public listing or when raising the next round of financing.

  • Why every biotech should create a valuation model
  • Common mistakes in valuations and how to avoid them
  • Gaining the upper hand in negotiations

Speaker: Thobias Thornblad, CEO of MSC Nordics

Event information